Story perspectives

FDA's Shift on Drug Approvals Sparks Public Scrutiny Concerns

9/14/2025

35 4

Summary

Story summary

The FDA aims to lessen reliance on advisory committees for drug approvals, citing overlap with complete response letters.
Critics warn this could hinder public scrutiny and expert input vital for informed decisions.
Former officials stress advisory meetings' role in ensuring transparency and expert feedback.
The FDA has conducted fewer advisory meetings since Trump's return, raising accountability concerns.
Upcoming ACIP meetings will discuss claims linking Covid vaccines to child deaths, based on often unverified VAERS data.

1 of 1

Story summary

The FDA aims to lessen reliance on advisory committees for drug approvals, citing overlap with complete response letters.
Critics warn this could hinder public scrutiny and expert input vital for informed decisions.
Former officials stress advisory meetings' role in ensuring transparency and expert feedback.
The FDA has conducted fewer advisory meetings since Trump's return, raising accountability concerns.
Upcoming ACIP meetings will discuss claims linking Covid vaccines to child deaths, based on often unverified VAERS data.